In the last decades, the possibility to use blood cells for delivery of pharmaceutical agents directly into a lesioned tissue has been given increasingly more attention. In the context of extracorporeal pharmacotherapy, the most promising approach is the use of autoerythrocytes possessed of unique morphological and physiological characteristics. Application of erythrocytes as containers for various drugs decreases the risk of side effects and pathologic immune reactions against encapsulated agents, permits to modify their pharmacokinetic and pharmacodynamic properties for reducing single and corse doses and intervals between them. The efficiency and safety of pharmaceutical agents introduced into erythrocytes have been confirmed in thousands of in vivo studies.